



Mice receiving brain tumor-derived CRCL vaccines develop specific T cell reactivity against brain tumor antigens.

VM/Dk mice were vaccinated with 2 x 20 μg SMA560-derived CRCL; splenocytes harvested, plated, and re-stimulated with the antigens shown (GPNMBecd = extracellular domain of glycoprotein non-metastatic B; Pep A and Pep B are GPNMB 15-mer peptides). Interferon-gamma output was quantified by ELISPOT assay.